Shares of Steris Plc (NYSE:STE) have been assigned a consensus recommendation of “Hold” from the six research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $90.67.

Several equities research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Steris Plc from a “buy” rating to a “sell” rating in a research report on Monday, November 6th. KeyCorp reiterated an “overweight” rating and set a $101.00 target price (up from $91.00) on shares of Steris Plc in a research report on Thursday, November 2nd. Raymond James Financial, Inc. lifted their target price on shares of Steris Plc from $95.00 to $100.00 and gave the stock an “outperform” rating in a research report on Monday, October 16th. Finally, BidaskClub downgraded shares of Steris Plc from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/11/steris-plc-ste-receives-90-67-average-price-target-from-analysts.html.

Steris Plc (NYSE STE) traded down $1.30 on Wednesday, hitting $86.85. 235,400 shares of the stock were exchanged, compared to its average volume of 475,037. Steris Plc has a one year low of $64.37 and a one year high of $93.39. The company has a current ratio of 2.80, a quick ratio of 2.18 and a debt-to-equity ratio of 0.48. The firm has a market cap of $7,497.37, a P/E ratio of 22.72 and a beta of 1.31.

Steris Plc (NYSE:STE) last posted its earnings results on Wednesday, November 1st. The medical equipment provider reported $0.94 EPS for the quarter, missing the consensus estimate of $0.95 by ($0.01). Steris Plc had a return on equity of 11.49% and a net margin of 5.59%. The business had revenue of $634.20 million for the quarter, compared to analyst estimates of $629.02 million. During the same quarter in the prior year, the business earned $0.89 earnings per share. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. equities analysts predict that Steris Plc will post 4.06 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 20th. Investors of record on Wednesday, November 22nd will be given a dividend of $0.31 per share. The ex-dividend date of this dividend is Tuesday, November 21st. This represents a $1.24 annualized dividend and a yield of 1.43%. Steris Plc’s dividend payout ratio is presently 73.81%.

In other news, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $85.69, for a total value of $856,900.00. Following the transaction, the chief executive officer now owns 83,270 shares in the company, valued at approximately $7,135,406.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Karen L. Burton sold 3,270 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $85.70, for a total transaction of $280,239.00. Following the completion of the transaction, the vice president now owns 11,807 shares in the company, valued at approximately $1,011,859.90. The disclosure for this sale can be found here. Insiders sold a total of 202,342 shares of company stock worth $17,729,692 in the last 90 days. Corporate insiders own 2.55% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of STE. Citigroup Inc. acquired a new position in shares of Steris Plc in the 2nd quarter worth approximately $206,000. Van Cleef Asset Management Inc acquired a new position in shares of Steris Plc in the 2nd quarter worth approximately $208,000. Cigna Investments Inc. New acquired a new position in shares of Steris Plc in the 2nd quarter worth approximately $209,000. BT Investment Management Ltd acquired a new position in shares of Steris Plc in the 2nd quarter worth approximately $210,000. Finally, Allegis Investment Advisors LLC acquired a new position in shares of Steris Plc in the 2nd quarter worth approximately $251,000. Hedge funds and other institutional investors own 93.91% of the company’s stock.

Steris Plc Company Profile

STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.

Receive News & Stock Ratings for Steris Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris Plc and related stocks with our FREE daily email newsletter.